Quest Diagnostics (DGX) — 2Q26 Earnings Preview

Timing note: The stated event date is Thursday, July 23, 2026—which is today, not tomorrow, based on the current date. This preview therefore addresses the setup immediately ahead of the 2Q26 report/call.

Investment framing

Quest enters 2Q with unusually strong operating momentum after a first quarter that exceeded its prior outlook and led management to raise full-year revenue and EPS guidance. The central question for investors is no longer whether growth has improved—it has—but how durable the organic components are once the large Corewell Health and Fresenius relationships are separated from underlying utilization, test mix, and consumer/advanced-diagnostics demand.

The setup is constructive, but expectations are higher. DGX closed at $209.87 on July 22, up roughly 21% year to date and about 2% above its post-1Q-earnings close, suggesting the market has recognized the better growth profile but has not fully re-rated the shares since the April print.

What matters most in 2Q

1. Organic growth quality—not simply reported volume

In 1Q, revenue rose 9.2% to $2.90 billion, while organic revenue grew 9.0% and adjusted EPS increased 13% to $2.50. Volume growth was a striking 10.8% organically, but roughly 7 percentage points came from Corewell and Fresenius. Excluding those two partnerships, underlying organic volume growth was still a healthy 3.8%.

The key 2Q debate will be whether that underlying growth rate held or improved. Investors should focus on:

• Organic volume excluding Corewell/Fresenius
• Organic revenue per requisition
• Tests per requisition and advanced-test mix
• Growth across the physician, hospital-reference, consumer, and enterprise channels

Management’s 1Q commentary pointed to broad-based strength: high-single-digit physician-channel growth, double-digit hospital growth, and robust consumer and wellness-partnership demand. Importantly, management said revenue per requisition would have risen about 2.5% excluding the mix effect of Corewell and Fresenius—evidence that advanced testing and test density are contributing rather than growth being purely lower-value routine volume.

2. Corewell and Fresenius: powerful revenue catalysts, mixed near-term margin signal

Corewell and Fresenius are expected to contribute approximately $250 million and $80 million–$100 million, respectively, to 2026 revenue growth—roughly 3.3% of annual revenue growth in aggregate.

That is material, but the investor interpretation is nuanced:

• These arrangements inflate requisition growth because they include more routine testing.
• They pressure consolidated revenue per requisition because of their lower-acuity mix.
• Margins should improve as the businesses ramp, particularly at Fresenius, which management expects to trend toward the enterprise-average margin over time.

For 2Q, a seemingly weak reported revenue-per-requisition figure should not automatically be viewed negatively. The more useful question is whether ex-partnership revenue per requisition and test-per-requisition remain positive.

3. Consumer health and advanced diagnostics remain the upside levers

Quest’s consumer strategy is evolving from a small direct-to-consumer business into a broader diagnostic “engine” for wellness platforms and wearables. In 1Q:

• Questhealth.com grew in the high-20% range.
• Wellness and wearable partnerships grew even faster, according to management.
• Management characterized the economics as at least in line with—and potentially modestly better than—enterprise-average margins, helped by cash-pay/client-bill economics and low denial exposure.

The most important advanced-diagnostics markers to watch are:

• Brain health / AD-Detect: management said the Alzheimer’s testing franchise more than doubled year over year in 1Q.
• Cardiometabolic and endocrine: Lp(a), ApoB, kidney, liver, and hormone testing have been important mix contributors.
• Women’s and reproductive health / autoimmune testing
• Haystack MRD oncology testing: likely not a material 2Q earnings driver yet, but progress on commercial adoption, reimbursement, and physician conversion could influence the long-term growth narrative.

A repeat of strong test-per-requisition growth would support the argument that Quest is gaining a structurally better mix of testing, not merely benefiting from contract implementations.

Guidance: room for another raise, but the bar is not low

Following 1Q, Quest raised 2026 guidance to:

2026 guidance	Current range
Revenue	$11.78B–$11.90B
Revenue growth	6.8%–7.8%
Adjusted EPS	$10.63–$10.83
Reported EPS	$9.58–$9.78
Cash from operations	~$1.75B
Capital expenditures	~$550M

Management indicated that just over 49% of annual revenue and EPS should occur in the first half, versus just over 50% in the second half. This places meaningful weight on the 2Q print: a strong quarter could create room for another upward revision, while merely meeting expectations may reinforce the existing full-year range rather than compel a raise.

My read: a guidance increase would likely require management confidence that underlying utilization, favorable test mix, and consumer-health demand are persisting—not simply continued ramping of Corewell and Fresenius.

Margin and EPS watch items

Positives

• The Invigorate productivity program continues to target 3% annual savings/productivity improvement.
• Automation and AI are being deployed in lab operations, customer-service workflows, and patient reporting.
• Lower interest expense aided 1Q EPS growth.
• Corewell/Fresenius margin profiles should improve as implementation and ramp costs are absorbed.

Offsets

• Wage inflation remains a recurring pressure.
• Project Nova—Quest’s multiyear order-to-cash modernization program—remains a $0.25 full-year adjusted-EPS headwind, with spending ramping in 2Q and more than 60% expected in the second half.
• Management has embedded $7M–$10M of higher fuel expense across 2Q–4Q, equivalent to roughly $0.05–$0.07 of EPS.
• 1Q cash from operations fell to $278M from $314M, primarily due to working-capital timing and higher bonus payments; investors should look for normalization in 2Q year-to-date cash conversion.

The most constructive 2Q outcome would combine solid organic growth with at least stable adjusted operating margin, showing that productivity is covering wage, fuel, and transformation-investment pressures.

Policy and reimbursement: not a 2Q earnings issue, but important for valuation

The immediate reimbursement backdrop appears manageable:

• Quest has assumed a 30-basis-point revenue impact in 2026 from ACA-related coverage changes, although management said it had not yet seen a meaningful impact in 1Q.
• Management does not expect the CMS CRUSH initiative to have a material direct impact on Quest, arguing its exposure to the laboratory tests identified as key spending drivers is minimal.
• The more consequential issue is PAMA reimbursement for 2027. Quest believes broader laboratory participation in current rate reporting could lead to more representative—and potentially better—rates. Conversely, uncertainty around legislation and the RESULTS Act remains an overhang.

This is principally a 2027 earnings-power and multiple issue, not a reason to expect a significant 2Q26 surprise.

What would make the quarter bullish?

1. Underlying organic volume remains in the mid-single digits or better, excluding Corewell and Fresenius.
2. Positive ex-partnership revenue per requisition, driven by test density and advanced diagnostics.
3. Consumer/wellness growth remains strong and management provides evidence of sustained partnership momentum.
4. Adjusted operating margin is resilient despite Nova spending and fuel costs.
5. Full-year revenue or adjusted-EPS guidance is raised again, or management signals material upside to the current range.
6. Clear evidence that Fresenius and Corewell are moving along expected margin-improvement curves.

What would disappoint?

1. Growth is disproportionately partnership-driven, with a noticeable slowdown in legacy physician or consumer demand.
2. Revenue per requisition weakens even after adjusting for the Corewell/Fresenius mix effect.
3. Margin performance implies Nova, labor, or fuel costs are outpacing productivity savings.
4. Management maintains guidance but turns more cautious on second-half utilization or consumer demand.
5. ACA enrollment attrition or reimbursement commentary becomes incrementally worse.
6. Haystack adoption/reimbursement progress remains slow enough to weaken confidence in the oncology growth option.

Bottom line

DGX’s 2Q report should be judged on organic growth durability and mix, rather than headline volume alone. The company has credible near-term revenue catalysts from Corewell and Fresenius, but the higher-quality indicators are continued growth in advanced diagnostics, consumer health, tests per requisition, and ex-partnership revenue per requisition.

Quest’s 1Q execution established a favorable setup: raised guidance, broad-based utilization, productivity gains, and attractive consumer-health momentum. For the stock to respond well, investors will likely want confirmation that this was not a one-quarter surge—and preferably another signal that the 2026 guidance range remains conservative.